Press releases

The New York Proton Center expands their RayStation installation

RaySearch Laboratories AB (publ) is pleased to announce that the New York Proton Center (NYPC) in the USA has committed to expand its RayStation®* installation, which will provide for the majority of the center’s proton treatment planning.

NYPC is the first and only facility delivering proton therapy in New York State. The center is operated as a consortium that includes Memorial Sloan Kettering Cancer Center, Montefiore Health System, and Mount Sinai Health System. NYPC opened in August 2019 and has fully integrated research and clinical trial programs. In 2022, the center purchased its first RayStation licenses to assess the benefits of the system. After a careful analysis, NYPC has decided to expand its use of RayStation, which will now be used for the majority of the center’s proton therapy planning. The purchase will also give the center access to advanced RayStation technology such as LET optimization, adaptive planning and AI autocontouring capabilities.

Dr. Haibo Lin, Director of Medical Physics of the New York Proton Center, says: “We worked very hard over the last two years to assess the technologies in RayStation and how it could help us provide the best possible plans for our patients, utilizing the most advanced features available to us as clinicians. We are pleased that we are now able to transition even more treatment planning to RayStation."

Jonathan Weinbach, CEO of the New York Proton Center, says: "Moving to a new treatment planning platform is a large task, both technically as well as financially. NYPC is glad to partner with RaySearch, who helped us demonstrate that we could plan faster, smarter and more efficiently, and even shorten treatment times for some patients. We look forward to a long collaboration."

Johan Löf, founder and CEO, RaySearch, says: “NYPC and its consortium have been excellent to work with. The team at NYPC is among the world leaders in the proton field, and it is especially gratifying that their decision to more fully transition to RayStation was based on extensive assessment of our products and service at all levels. We also look forward to working with NYPC and collaborating well into the future."

About New York Proton Center
The New York Proton Center is creating the gold standard for proton therapy, giving new hope to patients living with cancer. In partnership with leading academic medical centers – Memorial Sloan Kettering Cancer Center, Montefiore Health System, Mount Sinai Health System – the New York Proton Center brings together expert oncologists, clinical care teams, and researchers to improve cancer care and advance the clinical evidence for proton therapy. For additional information, please visit

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.  

RaySearch's software has been sold to over 1,000 clinics in 43 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at

About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.

* Subject to regulatory clearance in some markets.

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00